Aclaris Therapeutics Inc

ACRSNASDAQ · USD
5.57USD0.00 (+1.28%)
1310

Aclaris Therapeutics Inc (ACRS) Straddle

ACRS straddle scan found 38 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 59.3%.

Read more

Trading a ACRS straddle lets you take a pure volatility position on Aclaris Therapeutics Inc without committing to a direction. Aclaris Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate ACRS straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on ACRS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Aclaris Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the ACRS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.

In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the ACRS straddle is the cleanest expression of that view. Our scanner prices every ACRS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a ACRS straddle into a catalyst or short a ACRS straddle to harvest decay, the options straddle setups that matter are all in one place.

May 21, 202711.00$6.7024520%59.3%$17.70$4.300
Feb 19, 20279.00$4.3515420%58.9%$13.35$4.650
Mar 19, 202710.00$5.4518220%58.4%$15.45$4.550
Dec 18, 20267.00$2.359120%58.2%$9.35$4.6536
Dec 17, 202710.00$7.1045520%57.6%$17.10$2.905
Nov 20, 20267.00$2.086320%57.6%$9.08$4.93106
Feb 19, 202710.00$5.3315420%57.3%$15.33$4.680
May 21, 202710.00$6.0024520%57.1%$16.00$4.000
Dec 17, 20277.00$4.6045520%56.6%$11.60$2.402
Jan 15, 20279.00$4.2311920%56.5%$13.23$4.780

As of September 18, 2026

Find the right straddle before volatility moves

Track ACRS straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial